Clinical significance of serum ornithine carbamoyltransferase in patients with non-alcoholic steatohepatitis

Hepatology Research

Volumn 39, Issue 9, 2009, Pages 939-943

  Tokushige, Katsutoshi ^a   Hashimoto, Etsuko ^a   Noto, Haruka ^a   Yatsuji, Satoru ^a   Tobari, Maki ^a   Torii, Nobuyuki ^a   Taniai, Makiko ^a   Shiratori, Keiko ^a   Murayama, Hiroshi ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b YAMASA CORPORATION   (Japan)

Author keywords

Fibrosis; Non alcoholic steatohepatitis; Ornithine carbamoyltransferase

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ORNITHINE CARBAMOYLTRANSFERASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

EID: 69949090511     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00530.x     Document Type: Article

References (20)

1. Teli MR, James OFW, Burt AD, Bennet MK, Day CP. The natural history of nonalcoholic fatty liver: Follow-up study. Hepatology 1995; 22: 1714-9.
2. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis; summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-19.
3. Mofrad P, Contos MJ, Haque M et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-92.
4. Fracanzani AL, Valenti L, Bugianesi E et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology 2008; 48: 792-8.
5. Amarapurkar DN, Patel ND. Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values. Trop Gastroenterol 2004; 25: 130-4.
6. Shimada M, Hashimoto E, Kaneda H, Noguchi S, Hayashi N. Nonalcoholic steatohepatitis: Risk factors for liver fibrosis. Hepatol Res 2002; 24: 429-38.
7. Murayama H, Ikemoto M, Hamaoki M. Ornithine carbamyltransferase is a sensitive marker for alcohol-induced liver injury. Clin Chim Acta 2008; 10: 100-4.
8. Murayama H, Fukuda Y, Tsunekawa S, Ikemoto M, Nagata A. Ratio of serum ornithine carbamoyltransferase to alanine aminotransferase as a potent indicator for hepatocellular carcinoma. Clin Biochem 2007; 40: 1077-80.
9. Watanabe Y, Mori S, Fujiyama S, Sato T, Mori M. Clinical evaluation of serum ornithine carbamoyltransferase by enzyme-linked immunosorbent assay in patients with liver diseases. Enzyme Protein 1994-1995; 48: 18-26.
10. Murayama H, Ikemoto M, Fukuda Y, Nagata A. Superiority of serum type-I arginase and ornithine carbamyltransferase in the detection of toxicant-induced acute hepatic injury in rats. Clin Chim Acta 2008; 391: 31-5.
11. Pessayre D, Fromenty B. NASH: A mitochondrial disease. J Hepatol 2005; 42: 928-40.
12. Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008; 14: 193-9.
13. Mizutani A. Cytochemical demonstration of ornithine carbamoyltransferase activity in liver mitochondria of rat and mouse. J Histochem Cytochem 1968; 16: 172-80.
14. Brunt EM, Janney CG, Di Biscrglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staining the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
15. Kleiner DE, Brunt EM, Natta MV et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 131-21.
16. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 1997; 94: 6420-5.
17. Hashimoto E, Yatsuji S, Tobari M et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009; 44 (Suppl 19): 89-95.
18. Albano E. New concepts in the pathogenesis of alcoholic liver disease. Expert Rev Gastroenterol Hepatol 2008; 2: 749-59.
19. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 360-9.
20. Murayama H, Ikemoto M, Fukuda Y, Tsunekawa S, Nagata A. Serum level of ornithine carbamoyltransferase is influenced by the state of Kupffer cells. Clin Chim Acta 2007; 380: 170-4.